Medication follow-up in newborns with extremely low birth-weight

Pharmacy Practice

  • Catarine Vitor Loureiro1Post-graduate Program in Pharmaceutical Sciences, Federal University of Ceará. Fortaleza, CE, Brazil.
  • Marta Maria de França Fonteles2Pharmacy Department, Federal University of Ceará. Fortaleza, CE, Brazil.
  • Mylenne Borges Jácome Mascarenhas3Department of Pharmacy, Federal University of Ceará. Fortaleza, CE, Brazil.
  • Elana Figueiredo Chaves4Walter Cantídio School Hospital, Federal University of Ceará. Fortaleza, CE, Brazil.
  • Paulo Yuri Milen Firmino5Faculdade Metropolitana da Grande Fortaleza (FAMETRO). Fortaleza, CE, Brazil.

Volume 17 Issue 4 Pages 1-7

DOI: 10.18549/PharmPract.2019.4.1584

Abstract

Objective: The medication follow-up in infants with extremely low birth-weight in a neonatal intensive care unit is described, identifying drug-related problems (DRP), drug-related negative outcomes, and the relationship between the occurrence of DRP and birth-weight of newborns and their impact on pharmacotherapy and length of hospital stay. Methods: A descriptive and exploratory study was performed in which medication follow-up of a population of infants with extremely low birth-weight admitted to the neonatal intensive care unit of a government-run maternity hospital was carried out by clinical pharmacists. Monitoring comprised assessment of patients' pharmacotherapy needs through visits to the neonatal unit, evaluation of prescriptions and information on medical records, identification of issues associated with pharmacotherapy and follow-up of the newborns' clinical evolution to determine whether desired results were achieved. Results: The subjects were 33 infants characterized by extremely low weight at birth. Analysis of patients' pharmacotherapy showed that 39.4% (n=13) of the neonates presented some type of DRP, totaling 37 DRPs and a mean of 2.8 problems/patient. Fourteen drugs were identified with the occurrence of DRP. Vancomycin and cefepime were the most prevalent, with 18.9% (n=7). Occurrence of DRPs and several clinical characteristics of newborns and their pharmacotherapy were compared. The most prevalent drug-related negative outcomes identified were "untreated health problem" (40%, n=10) and "quantitative ineffectiveness" (32%, n=8). Pharmaceutical interventions were performed for all problems associated with pharmacotherapy, with a prevalence of "treatment day count correction" and "dose correction", both with 21.6% (n=8), and "correction of dosage" (16.2%, n=6). Conclusion: The research evidenced the role of the clinical pharmacist in the solution and prevention of drug-related problems, contributing with the multidisciplinary team to obtain a safe and effective pharmacotherapy. Further, current study confirmed that there is an association between the characteristics of the newborns under analysis (eg. birth-weight, pharmacotherapy) and the occurrence of drug-related problems.

Keywords

  • Infant
  • Extremely Low Birth Weight
  • Birth Weight
  • Intensive Care Units
  • Neonatal
  • Pharmaceutical Services
  • Pharmacists
  • Length of Stay
  • Patient Care Team
  • Follow-Up Studies
  • Brazil
Pharmacy Practice

Loading…